<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00755261</url>
  </required_header>
  <id_info>
    <org_study_id>J07133</org_study_id>
    <secondary_id>NA_00013238</secondary_id>
    <secondary_id>AVF3855s</secondary_id>
    <nct_id>NCT00755261</nct_id>
  </id_info>
  <brief_title>Phase II Study of Doxorubicin and Avastin® in Sarcoma.</brief_title>
  <official_title>Phase II Study of Doxorubicin and Avastin® for Patients With Advanced Soft-tissue Sarcomas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to find out if adding a drug called Avastin to an already
      approved regimen used for soft-tissue sarcoma, Doxorubicin, will improve overall survival,
      and slow disease progression. The study will also evaluate the overall safety of combining
      these drugs. It is not known if combining these drugs will improve outcome. Avastin has been
      approved for the treatment of metastatic carcinoma of the colon or rectum. It is not approved
      for the treatment of soft-tissue sarcoma when added to Doxorubicin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rationale for this trial is to improve the efficacy of prototypical anti-sarcoma
      chemotherapeutic regimen Doxorubicin when combined with Avastin®. Soft tissue sarcomas are
      highly vascular tumors and are therefore ideally suited to trials combining angiogenic
      inhibitors with chemotherapy. Several studies have revealed correlations between prognosis
      and surrogates for angiogenesis, including microvessel density, and circulating VEGF and
      basic fibroblast growth factor (bFGF). The aim of this study is to evaluate the safety and
      efficacy of Avastin® in combination with Doxorubicin for the treatment of advanced
      soft-tissue sarcomas.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study has been terminated due to low accrual.
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RECIST</measure>
    <time_frame>6 month PFS</time_frame>
    <description>Study was terminated because of low accrual.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Sarcoma</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Avastin and Doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with Avastin 15 mg/kg IV infusion plus doxorubicin 60 mg/M2 (body surface area) IV 6-hour infusion on Day 1 of each 21-day treatment cycle. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin</intervention_name>
    <description>Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.</description>
    <arm_group_label>Avastin and Doxorubicin</arm_group_label>
    <other_name>bevacizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.</description>
    <arm_group_label>Avastin and Doxorubicin</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically confirmed intermediate or high grade locally advanced or metastatic
             soft tissue sarcoma.

          2. The presence of measurable disease

          3. Normal renal function (spot dipstick &lt;2** or urine protein: creatinine ratio &gt;1.0

          4. Normal Hepatic function (total bilirubin within JOHC normal limits, transaminases (AST
             and ALT &lt;3 times upper limit of normal

          5. Hematologic parameters as defined as ANC &gt;1500/mm³ and Platelets &gt; 100,000/mm³.

          6. Performance status 0-1 on ECOG scale

          7. Use of effective means of contraception (men and women) in subjects of child-bearing
             age

          8. No prior use of mesna, adriamycin, ifosfamide or Avastin®.

          9. Baseline ECHO or MUGA with LVEF &gt; or = 50-60%.

         10. Age ≥ 18

        Exclusion Criteria:

          1. Major surgery within 28 days

          2. History of proteinuria &gt; 1+

          3. Current, recent (within 4 weeks of the first infusion of this study), or planned
             participation in an experimental drug study other than a Genentech-sponsored Avastin®
             cancer study

          4. Inadequately controlled hypertension (defined as systolic blood pressure &gt;150 and/or
             diastolic blood pressure &gt; 100 mmHg on antihypertensive medications)

          5. Any prior history of hypertensive crisis or hypertensive encephalopathy

          6. New York Heart Association (NYHA) Grade II or greater congestive heart failure (see
             Appendix E)

          7. History of myocardial infarction or unstable angina within 6 months prior to study
             enrollment

          8. History of stroke or transient ischemic attack within 6 months prior to study
             enrollment

          9. Symptomatic peripheral vascular disease

         10. Significant vascular disease (e.g., aortic aneurysm, aortic dissection)

         11. Evidence of bleeding diathesis or coagulopathy

         12. Current or recent (within 10 days of enrollment) use of aspirin (&gt;325 mg/day) or
             chronic use of other NSAIDs

         13. Current, ongoing treatment with full-dose warfarin or its equivalent (i.e.,
             unfractionated and/or low molecular weight heparin).

         14. Known central nervous system or brain metastases

         15. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 0, anticipation of need for major surgical procedure during the course of
             the study

         16. Core biopsy or other minor surgical procedure, excluding placement of a vascular
             access device, within 7 days prior to study enrollment

         17. Pregnant (positive pregnancy test) or lactating

         18. Proteinuria :creatinine (UPC) ratio ≥ 1.0 at screening or Urine dipstick for
             proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis
             at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of
             protein in 24 hours to be eligible).

         19. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to Day 0

         20. Serious, non-healing wound, ulcer, or bone fracture

         21. Known hypersensitivity to any component of Avastin®

         22. Inability to comply with study and/or follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine A Thornton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins SKCCC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins SKCCC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <results_first_submitted>April 15, 2015</results_first_submitted>
  <results_first_submitted_qc>May 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 8, 2015</results_first_posted>
  <last_update_submitted>May 7, 2015</last_update_submitted>
  <last_update_submitted_qc>May 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Only 4 subjects were accrued over 2 years. Study was closed due to slow accrual.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Avastin and Doxorubicin</title>
          <description>Patients will be treated with Avastin 15 mg/kg IV infusion plus doxorubicin 60 mg/M2 (body surface area) IV 6-hour infusion on Day 1 of each 21-day treatment cycle. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
Avastin: Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
Doxorubicin: The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Avastin and Doxorubicin</title>
          <description>Patients will be treated with Avastin 15 mg/kg IV infusion plus doxorubicin 60 mg/M2 (body surface area) IV 6-hour infusion on Day 1 of each 21-day treatment cycle. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
Avastin: Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
Doxorubicin: The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="45" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>RECIST</title>
        <description>Study was terminated because of low accrual.</description>
        <time_frame>6 month PFS</time_frame>
        <population>study was terminated because of low accrual (4 subjects enrolled/2 years)</population>
        <group_list>
          <group group_id="O1">
            <title>Avastin and Doxorubicin</title>
            <description>Patients will be treated with Avastin 15 mg/kg IV infusion plus doxorubicin 60 mg/M2 (body surface area) IV 6-hour infusion on Day 1 of each 21-day treatment cycle. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
Avastin: Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
Doxorubicin: The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.</description>
          </group>
        </group_list>
        <measure>
          <title>RECIST</title>
          <description>Study was terminated because of low accrual.</description>
          <population>study was terminated because of low accrual (4 subjects enrolled/2 years)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>none, study was terminated early because of low accrual.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Avastin and Doxorubicin</title>
          <description>Patients will be treated with Avastin 15 mg/kg IV infusion plus doxorubicin 60 mg/M2 (body surface area) IV 6-hour infusion on Day 1 of each 21-day treatment cycle. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
Avastin: Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
Doxorubicin: The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <description>Oral thrush, dehydration, no able to swallow medications. No oral intake x 5 days.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute renal failure</sub_title>
                <description>Known pelvic malignancy; limited urinary sx. Scr creatinine = 0.9. Unable to void 24- 36 hrs. No output with straight catheterization. Creatinine=5.3. Occurred prior to any oral study drug being taken. Not related to treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dysphagia -unable to swallow medications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>thrush</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christian Meyer, M.D., Ph.D.</name_or_title>
      <organization>SKCCC, Johns Hopkins University</organization>
      <phone>4105025940</phone>
      <email>cmeyer13@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

